Leadership Overhaul at Redcare Pharmacy Amid Profitability Challenges

Redcare Pharmacy is poised for a significant leadership transition at the highest level of its supervisory board. The upcoming Annual General Meeting in mid-April will see shareholders vote on the replacement of three long-standing positions. This shift in the company’s controlling body occurs during a complex period for the online pharmacy, which is navigating shrinking margins despite achieving record sales in prescription medications.

New Faces for a Digital Future

The company is bidding farewell to several veteran board members. Björn Söder and Jérôme Cochet, who have served on the supervisory board since the 2016 initial public offering, are stepping down alongside Jaska de Bakker. Nominated as their successors are Anja Hendel, Max Müller, and Peter Schmid von Linstow. Hendel’s background is seen as particularly valuable; her prior role as managing director at diconium, a Volkswagen subsidiary, is expected to bolster the firm’s digital strategy and technological transformation efforts.

Furthermore, the formal confirmation of Hendrik Krampe as the new Chief Financial Officer is on the agenda. Krampe brings more than two decades of experience to the role, having previously served as Finance Director for Amazon’s European marketplace. He assumes financial leadership at a critical juncture, as the business works to balance robust growth with the imperative for profitability.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Operational Headwinds Despite Revenue Growth

This personnel renewal unfolds against a backdrop of operational pressure. The introduction of electronic prescriptions has driven record revenue for Redcare’s prescription drug segment. However, this positive performance is offset by a slowdown in the traditionally high-margin over-the-counter (OTC) business. Growth in this segment decelerated to 9.2 percent in the fourth quarter of 2025, down from 17 percent previously. Consequently, the group’s gross margin contracted from 22.3 percent to 21.3 percent.

Compounding these challenges, management was compelled in early March to significantly revise its medium-term margin target downward from over eight percent to now over five percent. The market reaction was swift and severe: shares closed at €33.54 on Friday, marking a new 52-week low and reflecting a staggering year-to-date loss of approximately 74 percent.

Scheduled for April 15, the Annual General Meeting will effectively signal a generational shift in corporate governance. The newly constituted supervisory board will immediately face the core task of converting strong top-line growth into sustainable profitability. The market will await the first concrete indications of the company’s operational progress in the current year with the next quarterly figures, which are set for release on May 6.